Gilead stops RSV an­tivi­ral tri­als af­ter low in­ci­dence rates dur­ing re­cent sea­son

Gilead Sci­ences has ter­mi­nat­ed two Phase 2 stud­ies of an RSV treat­ment can­di­date called obelde­sivir.

The Cal­i­for­nia biotech end­ed a tri­al of the oral tablet …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER